Open Access
| Issue |
Med Sci (Paris)
Volume 36, Number 6-7, Juin–Juillet 2020
m/s / COVID-19
|
|
|---|---|---|
| Page(s) | 555 - 558 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2020106 | |
| Published online | 19 June 2020 | |
- Coronaviridae study group of the international committee on taxonomy of V. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5 : 536–44. [CrossRef] [PubMed] [Google Scholar]
- Tratner I. SRAS : 1. Le virus. Med Sci (Paris) 2003 ; 19 : 885–891. [CrossRef] [Google Scholar]
- Lee EYP, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis 2020; 20 : 384–5. [CrossRef] [PubMed] [Google Scholar]
- Jager S, Cimermancic P, Gulbahce N, et al. Global landscape of HIV-human protein complexes. Nature 2011 ; 481 : 365–370. [PubMed] [Google Scholar]
- James JS. Saquinavir (Invirase): first protease inhibitor approved–reimbursement, information hotline numbers. AIDS Treatment News 1995 ; 1–2. [Google Scholar]
- Hurst M, Faulds D. Lopinavir. Drugs 2000; 60 : 1371–9; discussion 80–1. [CrossRef] [PubMed] [Google Scholar]
- Capeau J, Caron M, Vigouroux C, et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l’infection par le VIH. Med Sci (Paris) 2006 ; 22 : 531–536. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000 ; 356 : 1423–1430. [CrossRef] [PubMed] [Google Scholar]
- Ravaud C, Pare M, Azoulay S, et al. Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors. Sci Rep 2017 ; 7 : 2986. [CrossRef] [PubMed] [Google Scholar]
- Ravaud C, Paré M, Yao X, et al. Resveratrol and HIV-protease inhibitors control UCP1 expression through opposite effects on p38 MAPK phosphorylation in human adipocytes. J Cell Physiol 2019 ; 235 : 1184–1196. [Google Scholar]
- Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005 ; 280 : 2238–2243. [CrossRef] [PubMed] [Google Scholar]
- Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Bioph Res Co 2009 ; 386 : 96–100. [CrossRef] [Google Scholar]
- Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014 ; 281 : 4085–4096. [CrossRef] [PubMed] [Google Scholar]
- Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science 2020; 368 : 409–12. [Google Scholar]
- Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003 ; 300 : 1763–1767. [Google Scholar]
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 : 1787–99. [Google Scholar]
- Lapatto R, Blundell T, Hemmings A, et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989 ; 342 : 299–302. [PubMed] [Google Scholar]
- Juckel D, Dubuisson J, Belouzard S. Les coronavirus, ennemis incertains. Med Sci (Paris) 2020, 36: 633–41. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.